Status:
COMPLETED
Personalized Evidence-based Medicine in Patients With Atrial Fibrillation
Lead Sponsor:
Center of Personalized Medicine, Pirogova
Collaborating Sponsors:
Center for New Medical Technologies, Novosibirsk, Russia
I.M. Sechenov First Moscow State Medical University
Conditions:
Adherence to Personalized EBM Anticoagulant Treatment in Patients at High Risk for Stroke
Eligibility:
All Genders
Brief Summary
A retrospective analysis
Detailed Description
4200 EMR of patients at high risk for stroke with 1-year follow-up will be enrolled in the current study and analyzed by clinical decision support systems (CDSS MedicBK) utilizing a core laboratory.
Eligibility Criteria
Inclusion
- EMR only if an ECG diagnosis (12-lead ECG, 24-h Holter, or other electrocardiographic documentation) confirming AF was made in patients at high risk for stroke by CHA2DS2-VASc (≥2 in men and ≥3 in women).
Exclusion
- No
Key Trial Info
Start Date :
January 10 2021
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
February 24 2021
Estimated Enrollment :
4200 Patients enrolled
Trial Details
Trial ID
NCT04774341
Start Date
January 10 2021
End Date
February 24 2021
Last Update
March 2 2021
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Evgeny Pokushalov
Novosibirsk, Russia, 630090